After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...
The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...
Analyst Michael Yee of Jefferies maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of ...
The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals' pill, Journavx, for short-term pain that often follows surgery or injuries. It’s the first new pharmaceutical ...
The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals' Journavx for short-term pain that often follows surgery or injuries. It’s the first new pharmaceutical approach to ...
For example, the Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) share price is up 83% in the last five years, slightly above the market return. Over the last year the stock price is up ...
Wall Street sees plenty of growth ahead, projecting an 8.2% jump in sales for 2025 as new products gain traction ... dollar markets, Vertex offers a compelling mix of stability and upside potential.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback